The emerging role of thalidomide therapy in HIV-infected patients

Infections in Medicine

Volumn 14, Issue 5, 1997, Pages

  Haslett, Patrick ^a   Freedman, Victoria H ^a   Kaplan, Gilla ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

AIDS wasting syndrome; Aphthous ulcers; Immunomodulation; Thalidomide; Tumor necrosis factor alpha

Indexed keywords

CYTOKINE; MONOCLONAL ANTIBODY; PENTOXIFYLLINE; PLACEBO; ROLIPRAM; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIINFLAMMATORY ACTIVITY; APHTHOUS ULCER; CACHEXIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG MECHANISM; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; NEUROPATHY; ORAL DRUG ADMINISTRATION; RASH; REVIEW; TERATOGENICITY; VIRUS INFECTION; WEIGHT REDUCTION;

EID: 16944367538     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Sheskin J: Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6:303-306, 1965.
2. Iyer CGS, Languillon J, Ramanujam K: WHO co-ordinated short-term double blind trial with thalidomide in the treatment of acute lepra reaction in male lepromatous patients. Bull World Health Organization 45:719-732, 1971.
3. Kovacs JA, Baseler M, Dewar RJ, et al: Increase in CD4 T-lymphocyte count with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: A preliminary study. N Engl J Med 332:567-575, 1995.
4. Teppler H, Kaplan G, Smith K, et al: Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response in patients with human immunodeficiency type 1 infection. J Infect Dis 167:291-298, 1993.
5. Andrieu JM, Lu W, Levy R: Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1 infected patients treated with prednisolone for one year. J Infect Dis 171:523-530, 1995.
6. Nogueira AC, Neubert R, Helge H, et al: Thalidomide and the immune response, 3: Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci 55:77-92, 1994.
7. Keenan RJ, Eiras G, Burckart GJ, et al: Immunosuppressive properties of thalidomide. Transplantation 52:908-910, 1991.
8. Shannon EJ, Ejigu M, Haile-Mariam H, et al: Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Lepr Rev 63:5-11, 1992.
9. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Nat Acad Sci USA 91:4082-5, 1994
10. Sampaio EP, Kaplan G, Miranda A, et al: The influence of thalidomide on the clinical and immunologic manifestations of erythema nodosum leprosum. J Infect Dis 168:408-414, 1993.
11. Sampaio EP, Sarno EN, Galilly R, et al: Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes. J Exp Med 173:699-703, 1991.
12. Corral LG, Muller GW, Moreira AL, et al: Selection of novel analogs of thalidomide with enhanced tumor necrosis factor-alpha inhibitory activity. Mol Med 2:506-515, 1996.
13. Weglicki WB, Stafford RE, Dickens BJ, et al: Inhibition of tumor necrosis factor-alpha by thalidomide in magnesium deficiency. Mol Cell Biochem 129:195-200, 1993.
14. Peterson PK, Hu S, Sheng WS, et al: Thalidomide inhibits tumor necrosis factor-alpha production by lipopolysaccharide and lipoarabinomannan-stimulated human microglial cells. J Infect Dis 172:1137-1140, 1995.
15. Descotes J, Tedone R, Evreux J-C: Enhancement of antibody response and delayed-type hypersensitivity by thalidomide in mice. Fundam Clin Pharmacol 2:493-497, 1988.
16. Tramontana JM, Utaipat U, Molloy A, et al: Thalidomide treatment reduces tumor necrosis factor and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1:384-397, 1995.
17. Vogelsang GB, Farmer ER, Allan DH, et al: Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326:1055-1058, 1992.
18. Hamza MH: Treatment of Behcet's disease with thalidomide. Clin Rheumatol 5:365-371, 1986.
19. Gutierrez-Rodriguez O: Thalidomide: A promising new treatment for rheumatoid arthritis. Arthritis Rheum 27:1118-1121, 1984.
20. Atra E, Sato EI: Treatment of cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 11:487-493, 1993.
21. Waters MFR, Laing AB, Ambikapathy A, et al: Treatment of ulcerative colitis with thalidomide. Br Med J 1:792, 1979.
22. Carlesimo M, Giustini S, Rossi A, et al: Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 32:866-869, 1995.
23. Klausner JD, Makonkawkeyoon S, Akarasewi P, et al: The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M tuberculosis infection. AIDS Res Hum Retroviruses 11:247-257, 1996.
24. Reyes-Teran G, Sierra-Madero JG, Delcerro VM et al: Effects of thalidomide on HIV-associated wasting syndrome: A randomized double blind, placebo-controlled clinical trial. AIDS 10:1501-1507, 1996.
25. Phelan J, Eisig S, Freedman PD, et al: Major aphthous-like ulcers in patients with AIDS. Oral Surg Oral Med Oral Pathol 71:68-72, 1991.
26. Muzycka BC, Blick M: Major aphthous ulcers in patients with HIV disease. Oral Surg Oral Med Oral Pathol 77:116-120, 1994.
27. Macphail LA, Greenspan D, Katz MH, et al: Recurrent aphthous ulcers in HIV infection: T-lymphocyte subsets. J Dent Res 70:331, 1991.
28. Regezi JA, Macphail LA, Richards DW, et al: A study of macrophages, macrophage-related cells, and endothelial adhesion molecules in recurrent aphthous ulcers in HIV-positive patients. J Dent Res 72:1549-1553, 1993.
29. Kotler DP, Reka S, Orenstein JM, et al: Chronic idiopathic esophageal ulceration in the acquired immunodeficiency syndrome: Characterization and treatment with corticosteroids. J Clin Gastroenterol 15:284-290, 1992.
30. Youle M, Clarbour J, Farthing C, et al: Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Br Med J 298:432, 1989.
31. Naum SM, Molloy P, Kania RJ, et al: Use of thalidomide in treatment and maintenance of idiopathic esophageal ulcers in HIV+ individuals. Dig Dis Sci 40:1147-1148, 1995.
32. Paterson DL, Georghiou PR, Allworth AM, et al: Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis 20:250-254, 1994.
33. Coodley GO, Loveless MO, Merrill TM: The HIV wasting syndrome: A review. J AIDS 7:681-694, 1994.
34. Grunfeld C, Feingold KR: Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 327:329-337, 1992.
35. Sutman U, Ockenga J, Hoogestraat L, et al: Resting energy expenditure and weight loss in human immunodeficiency virus-infected patients. Metabolism 42:1173-1179, 1993.
36. Macallan DC, Noble C, Baldwin C, et al: Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 333:83-88, 1995.
37. Rouzer CA, Cerami A: Hypertriglyceridemia associated with Trypanosoma brucei brucei infection in rabbits: Role of defective triglyceride removal. Mol Biochem Parasitol 2:31-38, 1980.
38. Tracey KJ, Morgello S, Koplin B, et al: Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. J Clin Invest 86:2014-2024, 1990.
39. Sharpstone D, Rashid N, Arthur G, et al: Faecal tumour necrosis factor-alpha and faecal alpha-one antitrypsin in HIV infection. Gut 35:40, 1994.
40. Haslett P, Hempstead M, Seidman C, et al: The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retrov. In press.
41. Berger TG, Hoffman CH, Thieberg MD: Prurigo nodularis and photosensitivity in AIDS: Treatment with thalidomide. J Am Acad Dermatol 33:837-838, 1995.
42. Maurer TA, Poncelet A, Badger J, et al: Thalidomide for the treatment of prurigo nodularis of HIV-infected patients. XI International Conference on AIDS, Vancouver, British Columbia, July 7-12, 1996, Abstract Tu B2274.
43. Georghiou PR, Allworth AM: Thalidomide in painful AIDS associated proctitis. J Infect Dis 166:939-940, 1992.
44. Sharpstone D, Rowbottom A, Nelson M, et al: The treatment of microsporidial diarrhea with thalidomide. AIDS 9:658-659, 1995.
45. Makonkawkeyoon S, Limson-Pobre R, Moreira A, et al: Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 90:5974-5978, 1993.
46. Fazely F, Dezube BJ, Allen-Ryan J, et al: Pentoxifylline (Trental) decreases the replication of the Human Immunodeficiency Virus type 1 in human peripheral blood mononuclear cells and in cultured T-cells. Blood 77:1653-1656, 1991.
47. Angel JB, Saget BM, Walsh SP et al: Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV replication. AIDS 9:1137-1144, 1995.
48. Dezube BJ, Pardee AP, Chapman B, et al: Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. J AIDS 6:787-794, 1993.
49. Dezube BJ, Lederman MM, Spritzler JG, et al: High-dose pentoxifylline in patients with AIDS: Inhibition of tumor necrosis factor production. J Infect Dis 171:1628-1632, 1995.
50. Wallis RS, Nsubuga C, Whalen C, et al: Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: A randomized, controlled trial. J Infect Dis 174:727-733, 1996.
51. Walker RE, Spooner KM, Kelly G, et al: Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis 174:63-68, 1996.
52. Chen T-L, Vogelsang GB, Petty B, et al: Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos 17:402-405, 1989.
53. Marriott JB, Cookson S, Carlin E, et al: A placebo controlled phase II trial of thalidomide in asymptomatic HIV positive patients: Clinical tolerance and effect on activation markers and cytokines. XI International Conference on AIDS, Vancouver, British Columbia, July 7-12, 1996. Abstract ThB176.
54. Waters MFR: An internally controlled double-blind trial of thalidomide in severe erythema nodosum leprosum. Lepr Rev 42:26-42, 1971.
55. Williams I, Weller IVD, Malin A, et al: Thalidomide hypersensitivity in AIDS. Lancet 337:436-437, 1991.
56. Haslett PAJ, Tramontana JM, Burroughs M, et al: Adverse reactions to thalidomide in patients infected with the human immundeficiency virus. Clin Infect Dis 1997. In press.
57. Gardner-Medwin JMM, Smith NJ, Powell RJ: Clinical experience with thalidomide in the management of severe oral and genital ulcération in conditions such as Behcet's disease: Use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 53:828-832, 1994.
58. Wulff CH, Hoyer H, Asboe-Hansen G, et al: Development of polyneuropathy during thalidomide therapy. Br J Dermatol 112:475-480, 1985.
59. Fuller GN, Jacobs JM, Guiloff RJ: Thalidomide, peripheral neuropathy and AIDS. Int J STD AIDS 2:369-370, 1991.
60. Ochonisky S, Verroust J, Bastuji-Garin S, et al: Thalidomide neuropathy incidence and clinicoelectrophysiological findings in 42 patients. Arch Dermatol 130:66-69, 1994.